Search

Your search keyword '"Visentin, Andrea"' showing total 9 results
Start Over Author "Visentin, Andrea" Journal annals of hematology
9 results on '"Visentin, Andrea"'

9. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study

Author

Vincenzo Pitini, Endri Mauro, Ines Wasle, Wolfgang Willenbacher, Andrea Visentin, Patrizia Mondello, Michael Mian, Salvatore Cuzzocrea, Simone Ferrero, Paola Ghione, Renato Zambello, Normann Steiner, Francesco Zaja, Mondello, Patrizia, Steiner, Normann, Willenbacher, Wolfgang, Wasle, Ine, Zaja, Francesco, Zambello, Renato, Visentin, Andrea, Mauro, Endri, Ferrero, Simone, Ghione, Paola, Pitini, Vincenzo, Cuzzocrea, Salvatore, and Mian, Michael

Subjects
Male, 0301 basic medicine, Lymphoma, Antibodie, Follicular lymphoma, Gastroenterology, Antineoplastic Agent, Antibodies, Monoclonal, Murine-Derived, 0302 clinical medicine, Retrospective Studie, immune system diseases, Prednisone, hemic and lymphatic diseases, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Bendamustine Hydrochloride, Aged, 80 and over, Lymphoma, Non-Hodgkin, Hematology, General Medicine, Middle Aged, Treatment Outcome, R-CHOP, Vincristine, Bendamustine, First line therapy, Follicular lymphoma, Indolent lymphoma, R-CHOP, Hematology, 030220 oncology & carcinogenesis, Bendamustine, Female, Rituximab, Human, medicine.drug, Murine-Derived, Adult, medicine.medical_specialty, Indolent lymphoma, First-line therapy, Aged, Antibodies, Antineoplastic Agents, Cyclophosphamide, Disease-Free Survival, Doxorubicin, Follow-Up Studies, Humans, Non-Hodgkin, Retrospective Studies, Follow-Up Studie, 03 medical and health sciences, Internal medicine, medicine, Antineoplastic Combined Chemotherapy Protocol, business.industry, Retrospective cohort study, medicine.disease, Surgery, Non-Hodgkin's lymphoma, Regimen, 030104 developmental biology, business
Abstract

The optimal first-line treatment for advanced low-grade non-Hodgkin lymphomas (LG-NHL) is still highly debated. Recently, the StiL and the BRIGHT trials showed that the combination of rituximab and bendamustine (R-B) is non-inferior to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with a better toxicity profile. Utilizing a retrospective analysis, we compared the efficacy and safety of both regimens in clinical practice. From November 1995 to January 2014, 263 LG-NHL patients treated with either R-B or R-CHOP were retrospectively assessed in seven European cancer centers. Ninety patients were treated with R-B and 173 with R-CHOP. Overall response rate was 94 and 92 % for the R-B and the R-CHOP group, respectively. The percentage of complete response was similar for both groups (63 vs. 66 % with R-B and R-CHOP, respectively; p = 0.8). R-B was better tolerated and less toxic than R-CHOP. The median follow-up was 6.8 and 5.9 years for the R-CHOP and the R-B group, respectively. Overall, no difference in progression-free survival (PFS) (108 vs. 110 months; p = 0.1) was observed in the R-B group compared to the R-CHOP cohort. Nevertheless, R-B significantly prolonged PFS in FL patients (152 and 132 months in the R-B and R-CHOP group, respectively; p = 0.05). However, this result was not verified in multivariate analysis probably due to the limits of the present study. We confirm that the R-B regimen administered in patients with LG-NHL is an effective and less toxic therapeutic option than R-CHOP in clinical practice. © 2016, Springer-Verlag Berlin Heidelberg.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results